Table 1.

Characteristics from aPL-positive patients who experienced a thrombosis during cohort participation*

Patient characteristics	aCL IgG (n=34)	aCL IgM (n=35)	aCL IgA (n=8)	Lupus anticoagulant (n=35)
Age at time of thrombosis (years)
<30	5 (15%)	3 (9%)	0 (0%)	7 (20%)
30–44	14 (41%)	11 (31%)	4 (50%)	13 (37%)
45–59	9 (26%)	16 (46%)	2 (25%)	10 (29%)
60+	6 (18%)	5 (14%)	2 (25%)	5 (14%)
Year at time of thrombosis
2000–2009	22 (65%)	21 (60%)	5 (63%)	22 (63%)
2010–2018	12 (35%)	14 (40%)	3 (37%)	13 (37%)
Number of prethrombosis aPL measures
2–4	3 (9%)	2 (6%)	1 (13%)	2 (6%)
5–9	6 (18%)	4 (11%)	1 (13%)	6 (17%)
10+	25 (74%)	29 (83%)	6 (75%)	27 (77%)
Proportion of prethrombosis aPL measures that were positive
<25%	14 (41%)	17 (49%)	3 (38%)	9 (26%)
25%–49%	3 (9%)	7 (20%)	1 (13%)	8 (23%)
50%–74%	7 (21%)	4 (11%)	1 (13%)	7 (20%)
75%–99%	7 (21%)	4 (11%)	1 (13%)	4 (11%)
100%	3 (9%)	3 (9%)	2 (25%)	7 (20%)
Type of thrombosis
Stroke	10 (29%)	8 (23%)	3 (38%)	8 (23%)
Myocardial infarction	3 (9%)	5 (14%)	2 (25%)	6 (17%)
Other arterial thrombosis	9 (26%)	9 (26%)	0 (0%)	8 (23%)
Digital gangrene	0 (0%)	2 (6%)	0 (0%)	1 (3%)
Deep vein thrombosis	11 (32%)	10 (29%)	2 (25%)	9 (26%)
Other venous thrombosis	1 (3%)	1 (3%)	1 (13%)	3 (9%)
Number of post-thrombosis aPL measures
1–4	1 (3%)	3 (9%)	1 (13%)	4 (11%)
5–9	9 (26%)	4 (11%)	2 (25%)	9 (26%)
10+	24 (71%)	28 (80%)	5 (63%)	22 (63%)
Proportion of post-thrombosis aPL measures that were positive
0%	14 (41%)	18 (51%)	4 (50%)	7 (20%)
<25%	6 (18%)	4 (11%)	0 (0%)	2 (6%)
25%–49%	5 (15%)	5 (14%)	0 (0%)	6 (17%)
50%–74%	4 (12%)	3 (9%)	1 (13%)	7 (20%)
75%+	3 (9%)	3 (9%)	1 (13%)	8 (23%)
100%	2 (6%)	2 (6%)	2 (25%)	5 (14%)

*This consists of those patients with at least two positive aPL tests before thrombosis. Some patients can appear in more than one column.

aCL, anticardiolipin; aPL, antiphospholipid.